Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000
MADISON, Wis., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $199.9 million and screened approximately 415,000 people with Cologuard during the quarter ended June 30, 2019. Second-quarter 2019 revenue and test...